Neoadjuvant therapy or upfront surgery for resectable  and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials

Neoadjuvant therapy may improve survival compared with upfront surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality evidence is lacking.

Source: European Journal of Cancer - November 24, 2021 Category: Cancer & Oncology Authors: Jacob L. van Dam, Quisette P. Janssen, Marc G. Besselink, Marjolein Y.V. Homs, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Roeland F. de Wilde, Johanna W. Wilmink, Casper H.J. van Eijck, Bas Groot Koerkamp, Dutch Pancreatic Cancer Group Tags: Original Research Source Type: research